言語を選択

CD30

CD30 詳細

英語名	Tumor necrosis factor receptor superfamily member 8	市販薬剤の数	1
治験薬の数	25	ターゲットの別称	CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8
研究＆開発段階	Approved

英語名	Tumor necrosis factor receptor superfamily member 8
ターゲットの別称	CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8
市販薬剤の数	1
治験薬の数	25
研究＆開発段階	Approved

CD30 製品リスト

属性
Protein (11)
製品ライブラリ
オンライン (11)
種
Human (10)Mouse (1)
タグ
Fc Tag (3)His Tag & Avi Tag (1)Llama IgG Fc Tag (1)His Tag (5)Fc Tag & Avi Tag (1)
マーカー
Unconjugated (4)Biotin-labeled (2)FITC Labeled (2)PE Labeled (1)AF488 Labeled (1)AF647 Labeled (1)

製品番号	種	発現システム	製品説明
HOT CD0-H52H5	Human	HEK293	Human CD30 / TNFRSF8 Protein, His Tag, low endotoxin
HOT CD0-H82E6	Human	HEK293	Biotinylated Human CD30 / TNFRSF8 Protein, Avitag™,His Tag (MALS verified)
HOT CD0-HP2E3	Human	HEK293	PE-Labeled Human CD30 / TNFRSF8 Protein, His Tag (Site-specific conjugation)
CD0-H5250	Human	HEK293	Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)
CD0-H82F4	Human	HEK293	Biotinylated Human CD30 / TNFRSF8 Protein, Fc,Avitag™ (MALS verified)
CD0-HA2H7	Human	HEK293	Alexa Fluor™ 488-Labeled Human CD30 / TNFRSF8 Protein, His Tag (HPLC verified)
CD0-HA2H9	Human	HEK293	Alexa Fluor™ 647-Labeled Human CD30 / TNFRSF8 Protein, His Tag
CD0-HF250	Human	HEK293	FITC-Labeled Human CD30 / TNFRSF8 Protein, Fc Tag
CD0-HF2H4	Human	HEK293	FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag
TN8-H5250	Human	HEK293	Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin

総数量11

CD30バックグランド

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

CD30分子の別称

TNFRSF8,CD30,D1S166E,Ki-1

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Acimtamig	AFM-13	Phase 2 Clinical	The University Of Texas MD Anderson Cancer Center	Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides	詳細
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center)		Phase 2 Clinical	Unc Lineberger Comprehensive Cancer Center	Hodgkin Disease; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Neoplasms, Germ Cell and Embryonal; Sezary Syndrome	詳細
Autologous CD30+ CAR T Cells therapy(New York Medical College)		Phase 2 Clinical	New York Medical College, University Of North Carolina At Chapel Hill	Hodgkin Disease	詳細
Itezocabtagene autoleucel	TT-11; TT11	Phase 2 Clinical	Tessa Therapeutics Ltd	Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Primary mediastinal B cell lymphoma	詳細
BRD-01	BRD-01	Phase 2 Clinical	Wuhan BioRaid Biotechnology Co Ltd	Hematologic Neoplasms; Hodgkin Disease	詳細
PRA-052	PRA-052; MK-8690; PR-600	Phase 2 Clinical	Prometheus Biosciences Inc	Colitis, Ulcerative	詳細
HSP-CAR-30	HSP-CAR-30	Phase 2 Clinical	Fundació Institut De Recerca De L	Hodgkin Disease; Lymphoma, T-Cell	詳細
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine)	CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta	Phase 2 Clinical	Pla General Hospital	Hodgkin Disease	詳細
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell)		Phase 1 Clinical	Immune Cell Inc	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	詳細
CD30.CAR-EBVST cell therapy (Baylor College of Medicine)	TT-11X	Phase 1 Clinical	Baylor College Of Medicine, Tessa Therapeutics Ltd	Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse	詳細
EBV-specific-CAR.CD30	EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs	Phase 1 Clinical	Baylor College Of Medicine, Methodist Hospital System, Texas Children'S Hospital	Hodgkin Disease; Lymphoma, Non-Hodgkin	詳細
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid)		Phase 1 Clinical	Wuhan BioRaid Biotechnology Co Ltd	Angioimmunoblastic T-cell Lymphoma; Hematologic Neoplasms; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral	詳細
B-0069 (Shanghai Pharmaceuticals Holding)	F0002-ADC; B-006(SCP)	Phase 1 Clinical	Shanghai Pharmaceuticals Holding Co Ltd	Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral	詳細
CD30.CAR	H-27721; CD30.CAR	Phase 1 Clinical	Baylor College Of Medicine	Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral	詳細
CD30 CAR-T Cells therapy (Unicar-Therapy Bio-Medicine Technology)	U29	Phase 1 Clinical	Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd	Lymphoma	詳細
ATLCAR.CD30.CCR4		Phase 1 Clinical	Unc Lineberger Comprehensive Cancer Center	Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Lymphoproliferative Disorders; Mycosis Fungoides; Neoplasms; Sezary Syndrome	詳細
Chimeric antigen receptor gene modified T cells therapy (Qilu Cell Therapy Engineering&Technology)		Phase 1 Clinical	Shandong Qilu Cell Treapy Engineering&Technology Co Ltd	Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell	詳細
Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital)		Phase 1 Clinical	Shanghai Tongji Hospital	Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell	詳細
CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)		Phase 1 Clinical		Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	詳細
SGN-35C	SGN-35C; PF-08046044	Phase 1 Clinical	Seagen Inc	Hodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral	詳細
Anti-CD30 CAR T-cell therapy		Phase 1 Clinical	Minghui (Nanjing) Gene Biotechnology Co Ltd	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	詳細
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit)		Phase 1 Clinical	The Medical College Of Wisconsin Nonprofit	Hodgkin Disease; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous	詳細
Anti-CD30 CAR-T cell therapy (National Cancer Institute)	Hu30-CD28z	Phase 1 Clinical	National Cancer Institute	Enteropathy-Associated T-Cell Lymphoma; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral	詳細
SGN-CD30C	SGN-CD30C	Phase 1 Clinical	Seattle Genetics Inc	Lymphoma	詳細
Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology)		Clinical	Shanghai YaKe Biotechnology Co Ltd	Hodgkin Disease	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Brentuximab vedotin	cAC10-vcMMAE; SGN-30; cAC10-Val-Cit-MMAE; cAC-10; SGD-1010; SGN-35	Approved	Seagen Inc	Adcetris, 安适利	United States	Lymphoma, Large-Cell, Anaplastic; Hodgkin Disease	Seagen Inc	2011-08-19	Anemia, Refractory, with Excess of Blasts; Carcinoma; Enteropathy-Associated T-Cell Lymphoma; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Hidradenitis Suppurativa; HIV Infections; Hodgkin Disease; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Papulosis; Mastocytosis, Systemic; Mesothelioma; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Germ Cell and Embryonal; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Kaposi; Scleroderma, Diffuse; Scleroderma, Systemic; Sezary Syndrome; Solid tumours	詳細

レビュー

R*** 2021-09-22
3評価
FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag
Our research group work with CAR-T therapy for the treatment of hematological malignancies, and use the Fitc-Labeled Human CD30 protein for detection of CAR30 cells in patients by flow cytometry. Our results are fantastic, because the observe consistency and a reproducible experiments by flow cytometry. The logistic speed is very effective and allows us to work always up to date with our projects.
1***22020-01-10
0評価
Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)
There are many CD30 products, with various tags. What I chose was the hFc tag protein. I also purchased CD30L for Fortebio experiment. The result was pretty good.